A clinical pharmacology, single topically dose study to evaluate the safety and pharmacokinetics of M605110 in patients with acne vulgaris
Phase 1
- Conditions
- Acne vulgaris
- Registration Number
- JPRN-jRCT2031220537
- Lead Sponsor
- Tomoyuki Nishiura
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 16
Inclusion Criteria
Patients with acne vulgaris who are 18 to 49 years of age at the time of informed consent
Exclusion Criteria
(1)Patients with a history or merger of cardiac, hepatic, plumonary, renal, hematologic, or other diseases considered inappropriate for paticipation in the clinical study
(2)Patients with inflamed cysts/induration
(3) Patients with diseases other than acne vulgaris at the planned application site of study drug
(4)Patients who are judged to be clinically abnormal by the principal (sub) investigator based on clinical tests, vital signs, and electrocardiogram
(5)Patients who are judged to be unsuitable as subject by the principal (sub) investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety, Pharmacokinetics
- Secondary Outcome Measures
Name Time Method